

PATENT USSN: 09/960,315
Atty Dkt: 034047.0041 (RIID 99-12A)

AMENDMENT**IN THE CLAIMS:**

Please amend the claims as follows:

1-16. Canceled

17. (Currently amended) A method of inducing a mean ELISA antibody titer of about 1×10^2 mg/ml or more against ricin toxin in a subject comprising administering to the subject an amount of a chemically deglycosylated ricin A-chain lacking about 50% of the mannose and most fucose residues present on the wild-type ricin toxin A-chain and having the ricin B-chain removed.

18. (Previously presented) The method of claim 17, wherein the deglycosylated ricin-A chain is chemically deglycosylated by treating a ricin A-chain with a mixture of sodium metaperiodate and sodium cyanoborohydride at a pH 3.5 for 1 hour at 4 °C.

19-20. Canceled.

21. (Original) The method of claim 17, wherein the amount is an immunogenic amount.

22. (Previously presented) The method of claim 21, wherein the immunogenic amount is about 0.01 μ g to about 100 μ g per kg of the weight of the subject.

23. (Previously presented) The method of claim 17, wherein two doses of the deglycosylated ricin A-chain are administered to the subject.

24. (Original) The method of claim 17, further comprising administering an adjuvant to the subject.

25. (Currently amended) A method for providing neutralizing antibodies against ricin toxin or preventing ricin intoxication in a subject comprising administering at least two doses of an

PATENT USSN: 09/960,315
Atty Dkt: 034047.0041 (RIID 99-12A)

immunogenic amount of a chemically deglycosylated ricin A-chain lacking about 50% of the mannose and most fucose residues present on the wild-type ricin toxin A-chain and having the ricin B-chain removed to the subject.

26-39. Canceled

40. (Presently presented) The method of claim 17, wherein the amount of deglycosylated ricin A-chain is administered in the form of a vaccine, an immunogenic composition, or a pharmaceutical composition.

41-43. Canceled

44. (Previously presented) The method of claim 40, wherein two doses of the vaccine, the immunogenic composition or the pharmaceutical composition provides neutralizing antibodies in a subject.

45. (Previously presented) The method of claim 40, wherein two doses of the vaccine, the immunogenic composition or the pharmaceutical composition prevents ricin intoxication in a subject.

46. (Previously presented) The method of claim 40, wherein the vaccine, the immunogenic composition or the pharmaceutical composition further comprises an adjuvant.